Perioperative erythropoietin protects the CNS against ischemic lesions in patients after open heart surgery

Wiener Klinische Wochenschrift

Volumn 128, Issue 23-24, 2016, Pages 875-881

  Lakič, Nikola ^a   Mrak, Miha ^a   Šušteršič, Miha ^a   Rakovec, Peter ^a   Bunc, Matjaž ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Erythropoietin; Ischemic lesions; Magnetic resonance imaging; Neurologic dysfunction; Open heart surgery

Indexed keywords

LACTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; NEURON SPECIFIC ENOLASE; NEURON SPECIFIC ENOLASE A; NEURON SPECIFIC ENOLASE B; PLACEBO; PROTEIN S 100; PROTEIN S100A; PROTEIN S100B; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ERYTHROPOIETIN; NEUROPROTECTIVE AGENT;

AGED; ANTERIOR CEREBRAL ARTERY; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; BRAIN PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE CEREBRAL ARTERY; NEUROLOGICAL COMPLICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN HEART SURGERY; OPERATION DURATION; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PNEUMONIA; POSTERIOR CEREBRAL ARTERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; CORONARY ARTERY BYPASS GRAFT; DIAGNOSTIC IMAGING; HEART SURGERY; PLACEBO EFFECT; PREMEDICATION; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; THORACOTOMY; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPROTECTIVE AGENTS; PLACEBO EFFECT; PREMEDICATION; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; THORACOTOMY; TREATMENT OUTCOME;

EID: 84984817930     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-016-1063-0     Document Type: Article

References (32)

1. Hogue CW, Murphy SF, Schechtman KB, et al. Risk factors for early or delayed stroke after cardiac surgery. Circulation. 1999;100:642–7.
2. Hogue CW, Barzilai B, Pieper KS, et al. Sex differences in neurological outcomes and mortality after cardiac surgery: a society of thoracic surgery national database report. Circulation. 2001;103:2133–7.
3. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. N Engl J Med. 2001;344:395–402.
4. Arrowsmith JE, Grocott HP, Reves JG, et al. Central nervous system complications of cardiac surgery. Br J Anaesth. 2000;84:378–93.
5. Van Dijk D, Keizer AM, Diephuis JC, et al. Neurocognitive dysfunction after coronary artery bypass surgery: a systematic review. J Thorac Cardiovasc Surg. 2000;120:632–9.
6. Shroyer AL, Coombs LP, Peterson ED, et al. 30-day operative mortality and morbidity risk models. Ann Thorac Surg. 2003;75:1856–64.
7. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment ofacute ischemic stroke. Stroke. 2009;40:647–56.
8. Ehrenreich H, Timner W, Sirén AL. A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfus Apher Sci. 2004;31:39–44.
9. Mahanna EP, Blumenthal JA, White WD, et al. Defining neuropsychological dysfunction after coronary artery bypass grafting. Ann Thorac Surg. 1996;61:1342–7.
10. Jönsson H, Johnsson P, Alling C, et al. S100beta after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome. Ann Thorac Surg. 1999;68:2202–8.
11. Herrmann M, Ebert AD, Galazky I, et al. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke. 2000;31:645–50.
12. Donato R. Functional roles of S100 proteins, calcium-binding proteinsof the EF-hand type. Biochim Biophys Acta. 1999;1450:191–231.
13. Hogue CW Jr, Palin CA, Arrowsmith JE. Cardiopulmonary bypass management and neurologicoutcomes: an evidence-based appraisal of current practices. Anesth Analg. 2006;103:21–37.
14. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8(8):495–505.
15. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry. 2004;9:42–54.
16. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant. 1999;14:22–8.
17. Lipsic E, Schoemaker RG, van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006;48:2161–7.
18. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999–1007.
19. Miskowiak K, O’Sullivan U, Harmer CJ. Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biol Psychiatry. 2007;62:1244–50.
20. Nagpal AD, Bhatnagar G, Cutrara CA, et al. Early outcomes of coronary artery bypass with and without cardiopulmonary bypass in octogenarians. Can J Cardiol. 2006;22:849–53.
21. Zanatta P, Forti A, Minniti G, et al. Brain emboli distribution and differentiation during cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2013;27(5):865–75. doi:10.1053/j.jvca.2012.12.022.
22. Douglas JM, Spaniol SE. A multimodal approach to the prevention of postoperative stroke in patients undergoing coronary artery bypass surgery. Am J Surg. 2009;197:587–90.
23. Masabni K, Raza S, Blackstone EH, et al. Does preoperative carotid stenosis screening reduce perioperative stroke in patients undergoing coronary artery bypass grafting? J Thorac Cardiovasc Surg. 2015;149(5):1253–60.
24. Lee EJ, Choi KH, Ryu JS, et al. Stroke risk after coronary artery bypass graft surgery and extent of cerebral artery atherosclerosis. J Am Coll Cardiol. 2011;57:1811–8.
25. Gottesman RF, Sherman PM, Grega MA. Watershed strokes after cardiac surgery: diagnosis, etiology, and outcome. Stroke. 2006;37:2306–11.
26. Lakic N, Surlan K, Jerin A, et al. Importance of erythropoietin in brain protection aftercardiac surgery: a pilot study. Heart Surg Forum. 2010;13:185–9.
27. Lipsic E, Westenbrink BD, van der Meer P, et al. Erythropoietin induces neovascularisation and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46(1):125–33.
28. Sakanaka M, Wen TC, Matsuda S, et al. Invivo evidence that erythropoietin protects neurons fromischemic damage. Proc Natl Acad Sci USA. 1998;95:4635–40.
29. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons fromacute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002;99:10659–64.
30. Bokesch PM, Izykenova GA, Justice JB, et al. NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke. 2006;37:1432–6.
31. Stolz E, Gerriets T, Kluge A, et al. Diffusion-weighted magnetic resonance imaging and neurobiochemical markers after aortic valve replacement: implication for future neuroprotective trials? Stroke. 2004;35:888–92.
32. Dambinova SA, Khounteev GA, Izykenova GA, et al. Blood test detecting autoantibodies to N‑methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49:1752–62.